Skip to main navigation
Company Logo
  • About
    • About Overview
    • Leadership
    • Careers
  • Product
    • RECELL® System
  • Clinical Development
    • Pipeline/Clinical Trials
    • Patient Outcomes
    • Proof Assets
  • News & Media
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Annual Reports & Proxy
    • Stock Information
    • Corporate Governance
    • FAQ
    • Email Alerts
    • Contact
  • Contact
  • Search
  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
  • Annual Reports & Proxy
  • Stock Information
  • Corporate Governance
  • FAQ
  • Email Alerts
  • Contact
global

Investors: Release Details

FDA Approves IDE Amendment to AVITA's Vitiligo Pivotal Study

August 17, 2021
96d78f65-482d-4312-a66b-2f7bfbe725c9.pdf 418.9 KB
AVITA Medical, Inc. Logo with tag

Contact Investor Relations

Ben Atkins
VP, Investor Relations and Corporate Communications
investor@avitamedical.com

Request Email Alerts

® 2026 AVITA Medical, Inc.
  • Terms of Use
  • Privacy Policy
  • CA Compliance
  • Social Media
  • CCPA
  • Compliance and Ethics
  • Important Safety Information

Social Media

  • Twitter (opens in new window)
  • Linkedin (opens in new window)